Resources>Antibody Industry Trends>Week 3, Apr 2024: Bispecific ADCs

Week 3, Apr 2024: Bispecific ADCs

Biointron 2024-04-16 Read time: 2 mins
bsadcs.jpg
Image credit: DOI: 10.1016/j.apsb.2024.01.009

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently. 

Last week, a paper published in Nature demonstrated the construction of a novel BsADC targeting HER2 and HER3 with more potent therapeutic efficacy against breast cancer over monospecific ADCs. It potently inhibited the viability of MCF7, JIMT-1, BT474, BxPC-3 and SKOV-3 cancer cells in vitro.  

Meanwhile, ProfoundBio’s novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models. Set to enter clinical trials by this year, the BsADC has the potential to treat multiple tumor types and was built on the clinically validated sesutecan platform. 

Also last month, a paper described a novel T cell-redirecting anti-GPRC5D x CD3 bispecific antibody with potent antitumor activity in multiple myeloma (MM) preclinical models. Their results show that the BsADC as a monotherapy and combination therapy with immunomodulatory drugs (IMiDs) could be a highly potent and effective treatment approach for a wide population of MM patients.

Recommended Articles
Biointron Insights: Antibody Industry Trends (Q3 2026 Insights, Trends & Analysis)

Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events a……

Sep 30, 2026
November 2026: Bispecifics x AI: From Design to Clinic

Bispecific antibodies (BsAbs) can bind two different antigens simultaneously, of……

Nov 09, 2026
Week 1, November 2026: VNAR vs. VHH: What's the Difference Between Shark and Camelid Single-Domain Antibodies?

When we think of antibodies, sharks and alpacas probably aren't the first an……

Nov 03, 2026
Week 3, October 2026: The Evolving Role of Biomarkers in Antibody-Based Cancer Therapies

Antibody-based cancer therapies have expanded treatment options across multiple ……

Oct 21, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.